Full text is available at the source.
Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting
Semaglutide's impact on one-year medical costs for overweight and obese patients in the US
AI simplified
Abstract
Patients treated with semaglutide 2.4 mg had 37% lower incidence of all-cause inpatient visits compared to non-users of obesity medication.
- Semaglutide treatment resulted in a 21% lower incidence of emergency room visits for all causes.
- The incidence of obesity-related inpatient visits decreased by 45% among those treated with semaglutide.
- Patients receiving semaglutide experienced a 29% reduction in obesity-related emergency room visits.
- Total medical costs were 11% lower for patients treated with semaglutide compared to non-users.
- Savings observed at 12 months were $3,342 for all-cause costs and $2,408 for obesity-related costs.
AI simplified